PD-L1 Archives - BJBMS Viewpoints

June 30, 2022

Latest posts

[ June 28, 2022 ] New Impact Factor (2021) for BJBMS is 3.759 News
[ June 27, 2022 ] PLCE1 gene might affect osteosarcoma immune status Author Summary
[ June 6, 2022 ] Serum microRNAs found to be promising diagnostic tools for papillary thyroid carcinoma Author Summary
[ June 3, 2022 ] Video summary: Efficacy of adjunctive photodynamic therapy in stage II – IV grade C Periodontitis Video Summary
[ June 1, 2022 ] The Reviewer of the Month for June 2022: Dr. Teodora Stankova Reviewer of the month

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

July 22, 2017 0

Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

June 9, 2017 0

Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]

BJBMS Viewpoints

Science in plain words

PD-L1

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

What matters the most when choosing the journal to submit your article?